EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Validation of Small‐Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus

Christina Karhan, Svenja M. Sake, Melanie Urbanek‐Quaing, Diletta Bergamo, Jessica Rückert, Jiabin Huang, Christina Grethe, Antonia P. Gunesch, Anne Kühnel, Birthe Reinecke, Nicole Fischer, Thomas F. Schulz, Thomas Pietschmann, Anna K. H. Hirsch

ChemMedChem · 2026-10-28 · 21 (20)

DOI: 10.1002/cmdc.70501 ↗
AbstraktBibliografické údaje

Abstrakt

Respiratory syncytial virus (RSV) is a major cause of severe respiratory infections worldwide, particularly in infants, young children, and elderly individuals. Despite the availability of preventive options such as vaccines and monoclonal antibodies, effective antiviral therapies for acute infections remain limited. Therefore, we investigated small‐molecule entry inhibitors identified in a high‐throughput campaing and evaluated the most promising candidates in detail by performing resynthesis and determining their antiviral activity. Unfortunately, analytical investigations by nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography–mass spectrometry (LC–MS) revealed discrepancies between the screening samples and the resynthesized compounds for two compound classes, highlighting the complexity of hit validation and the potential influence of impurities. By publishing these results, we aim not only to underscore the importance of rigorous analytical and biological validation in screening campaigns but also to support the development of improved strategies for identifying reliable RSV inhibitors. We also believe it is important to publish false‐positive hits to avoid time efforts on projects that assume such compounds as genuine hits.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →